NCT02549989 - Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 23, 2022

Study Completion Date

March 23, 2022

Conditions

Endometrial CancerRecurrent Endometrial Cancer

Interventions

DRUG

LY3023414

Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER